Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand [Seeking Alpha]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Seeking Alpha
VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth. Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF. Guidance for 2026 targets $12.95–$13.1 billion in total revenue, with non-CF products expected to contribute over $500 million. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Olga Yastremska/iStock via Getty Images The last time I spoke about Vertex Pharmaceuticals VRTX ) it was with a Seeking Alpha article entitled " Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy ." With respect to this article, I mentioned that the More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex to Announce First Quarter 2026 Financial Results on May 4thBusiness Wire
- Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance]Yahoo! Finance
- Vertex Pharma wins FDA label expansion for cystic fibrosis therapies [Seeking Alpha]Seeking Alpha
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/12/26 - Beat
VRTX
Sec Filings
- 4/3/26 - Form 4
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- VRTX's page on the SEC website